AU2020218366A1 - Valproic acid compounds and Wnt agonists for treating ear disorders - Google Patents

Valproic acid compounds and Wnt agonists for treating ear disorders Download PDF

Info

Publication number
AU2020218366A1
AU2020218366A1 AU2020218366A AU2020218366A AU2020218366A1 AU 2020218366 A1 AU2020218366 A1 AU 2020218366A1 AU 2020218366 A AU2020218366 A AU 2020218366A AU 2020218366 A AU2020218366 A AU 2020218366A AU 2020218366 A1 AU2020218366 A1 AU 2020218366A1
Authority
AU
Australia
Prior art keywords
valproic acid
acid compound
systemic
pharmaceutically acceptable
wnt agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020218366A
Other languages
English (en)
Inventor
Christopher Loose
Will MCLEAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korro Bio Inc
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of AU2020218366A1 publication Critical patent/AU2020218366A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020218366A 2019-02-08 2020-02-07 Valproic acid compounds and Wnt agonists for treating ear disorders Abandoned AU2020218366A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803345P 2019-02-08 2019-02-08
US62/803,345 2019-02-08
PCT/US2020/017352 WO2020163812A1 (en) 2019-02-08 2020-02-07 Valproic acid compounds and wnt agonists for treating ear disorders

Publications (1)

Publication Number Publication Date
AU2020218366A1 true AU2020218366A1 (en) 2021-09-16

Family

ID=69771188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020218366A Abandoned AU2020218366A1 (en) 2019-02-08 2020-02-07 Valproic acid compounds and Wnt agonists for treating ear disorders

Country Status (5)

Country Link
US (1) US20220133740A1 (https=)
EP (1) EP3920885A1 (https=)
JP (1) JP2022520671A (https=)
AU (1) AU2020218366A1 (https=)
WO (1) WO2020163812A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
CN100335479C (zh) 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
JP2003516974A (ja) 1999-12-17 2003-05-20 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピラジンベースインヒビター
AU2001230026A1 (en) 2000-02-04 2001-08-14 Novo-Nordisk A/S 2,4-diaminothiazole derivatives
JP2001275095A (ja) 2000-03-27 2001-10-05 Sony Corp 通信方法、通信サービス装置、通信端末装置および通信システム
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
AU783615B2 (en) 2000-05-11 2005-11-17 Consejo Superior De Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase GSK-3
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
US7109199B2 (en) 2000-09-22 2006-09-19 Smithkline Beecham Corporation Pyrazolopyridines and pyrazolopyridazines as antidiabetics
WO2002032896A1 (en) 2000-10-16 2002-04-25 Novo Nordisk A/S Furazanyl-triazole derivates for the treatment of diseases
BR0116468A (pt) 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
CA2437215A1 (en) 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
IL161663A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
WO2003066629A2 (en) 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
EP1504368A4 (en) 2002-02-11 2008-01-23 Novartis Vaccines & Diagnostic Method for crystallizing human gsk3 and novel crystal structure thereof
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
ES2289274T3 (es) 2002-03-08 2008-02-01 Eli Lilly And Company Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
WO2003095452A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
JP2005531607A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤として置換ピロリン
EP1513830A1 (en) 2002-06-05 2005-03-16 Janssen Pharmaceutica N.V. Bisindolyl-maleimid derivatives as kinase inhibitors
EP1739087A1 (en) 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
DE60333762D1 (de) 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
CN1717391A (zh) 2002-10-21 2006-01-04 希龙公司 糖元合成酶激酶3的抑制剂
EP1438942A1 (en) 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
CA2520590A1 (en) 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
EP1654255B1 (en) 2003-06-13 2008-08-27 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
AU2004260738B2 (en) 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
EP1781659B1 (en) 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
JP2005145928A (ja) 2003-11-19 2005-06-09 Yamanouchi Pharmaceut Co Ltd ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体を有効成分とする医薬組成物
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
JP2005298437A (ja) 2004-04-15 2005-10-27 Astellas Pharma Inc ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
US8771754B2 (en) 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006075023A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
EP1847531A4 (en) 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
EP1879591B8 (en) 2005-05-04 2012-04-04 DeveloGen Aktiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
US8778919B2 (en) 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
WO2007008514A2 (en) 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
EP1981500A4 (en) 2006-02-02 2010-08-25 Astrazeneca Ab PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4-YLMETHYL) PYRIDINE-2-YL] -1H-INDOL-5-CARBONITRIL AS FREE BASE OR SALT
WO2007089193A1 (en) 2006-02-02 2007-08-09 Astrazeneca Ab A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof
JP2009528344A (ja) 2006-02-28 2009-08-06 アストラゼネカ・アクチエボラーグ インドール誘導体の新規な塩及び医薬におけるその使用
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
CA2645376C (en) 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
US7851468B2 (en) 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
CN101528729A (zh) 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
ES2410955T3 (es) 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0810216A2 (pt) 2007-04-18 2014-10-21 Astrazeneca Ab Processo para a preparação de composto, composto, e, método de tratamento de distúrbio bipolar
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
EP2170870B1 (en) 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
DE102007032977A1 (de) 2007-07-16 2009-01-22 Universität Tübingen Neue Cyclische Amide, Verfahren zu deren Herstellung und ihre Verwendung
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
CN102351880B (zh) 2007-09-11 2014-11-12 杏林制药株式会社 作为gsk-3 抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
US8476261B2 (en) 2007-09-12 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as GSK-3 inhibitors
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
US8455648B2 (en) 2008-04-24 2013-06-04 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US20090291982A1 (en) 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US20130039998A1 (en) 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
MX2011009414A (es) 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
SG175207A1 (en) 2009-04-14 2011-11-28 Lilly Co Eli Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
KR20120120307A (ko) 2010-01-19 2012-11-01 아스트라제네카 아베 피라진 유도체
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
DE102011081172B4 (de) 2011-08-18 2013-05-08 Schott Ag Verpackungseinheit für ein auf einen Wickelkern gerolltes Glas
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
JP6073377B2 (ja) 2012-02-24 2017-02-01 エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
TW201417817A (zh) 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
RS58700B1 (sr) 2012-10-12 2019-06-28 Broad Inst Inc Gsk3 inhibitori i postupci njihove primene
JP6476127B2 (ja) 2012-11-29 2019-02-27 タカラ バイオ ヨーロッパ アーベー ヒト多能性幹細胞由来肝細胞様細胞の成熟
ES2693718T3 (es) 2013-11-06 2018-12-13 Bristol-Myers Squibb Company Derivados de piridina sustituidos útiles como inhibidores de GSK-3
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
CA3014659A1 (en) * 2016-03-02 2017-09-08 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
WO2018098411A1 (en) 2016-11-28 2018-05-31 Bristol-Myers Squibb Company Gsk-3 inhibitors
EP3562827A1 (en) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3592747A1 (en) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof

Also Published As

Publication number Publication date
WO2020163812A1 (en) 2020-08-13
EP3920885A1 (en) 2021-12-15
US20220133740A1 (en) 2022-05-05
JP2022520671A (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
RS53591B1 (sr) Farmaceutske kompozicije za tretman poremećaja unutrašnjeg uva
EP2858647B1 (en) H4 receptor inhibitors for treating tinnitus
US11162071B2 (en) Compositions and methods for generating hair cells by upregulating JAG-1
JP2012524073A (ja) 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
Yu et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel
TW202103692A (zh) 用於治療聽力損失之組合物及方法
AU2020218366A1 (en) Valproic acid compounds and Wnt agonists for treating ear disorders
EP3920886A1 (en) Taz activators and wnt agonists for treating ear disorders
JP5209718B2 (ja) 眼球前区炎症を治療し又は制御するための組成物及び方法
US20200080055A1 (en) Compositions and methods for generating hair cells by upregulating pi3k
JP2022523158A (ja) エピジェネティック標的を阻害することにより有毛細胞を生成するための組成物及び方法
US20230183475A1 (en) Gelling solutions for administration of compounds to the inner ear
JP7332602B2 (ja) 経皮薬物送達システムおよびその使用方法
WO2011049954A2 (en) Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
TW201004633A (en) Auris formulations for treating otic diseases and conditions
HK1209321B (en) H4 receptor inhibitors for treating tinnitus

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period